Lilly teams up with SanegeneBio in a US$1.2 billion RNAi deal to develop tissue-targeted metabolic therapies using ...

Some stocks are similar to the tortoise in Aesop's famous fable, "The Tortoise and the Hare." Others are like the hare. But ...

SanegeneBio is responsible for discovering and identifying optimised RNAi molecules for each programme through its LEAD platform.

Responsible for global chickpea losses of around USD 330 million annually, the pest not only threatens chickpeas but also ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 25, 2025, at 4:30 p.m. ET to discuss its financial results for the 2025 ...

The aggregate gross proceeds to Benitec from the underwritten public offering and the concurrent registered direct offering are expected to be approximately $100 million, prior to deducting ...

Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- ...

A record-breaking 4,432 scientific abstracts accepted at the American Heart Association’s meeting here adorned posters, ...

A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.

Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.

Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, ...

Company plans to initiate a Phase 1 study in early 2026 with initial human data expected late 2026 Company's first clinical-stage program headlines a diverse and novel pipeline poised to deliver ...